| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| David Erritzoe, Tommaso Barba, Meg J Spriggs, Fernando E Rosas, David J Nutt, Robin Carhart-Harri. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. Journal of psychopharmacology (Oxford, England). 2024-03-23. PMID:38520045. |
there is growing evidence for the therapeutic effects of the psychedelic drug psilocybin for major depression. |
2024-03-23 |
2024-03-26 |
human |
| Jakub Vohryzek, Joana Cabral, Louis-David Lord, Henrique M Fernandes, Leor Roseman, David J Nutt, Robin L Carhart-Harris, Gustavo Deco, Morten L Kringelbac. Brain dynamics predictive of response to psilocybin for treatment-resistant depression. Brain communications. vol 6. issue 2. 2024-03-22. PMID:38515439. |
brain dynamics predictive of response to psilocybin for treatment-resistant depression. |
2024-03-22 |
2024-03-24 |
Not clear |
| Jakub Vohryzek, Joana Cabral, Louis-David Lord, Henrique M Fernandes, Leor Roseman, David J Nutt, Robin L Carhart-Harris, Gustavo Deco, Morten L Kringelbac. Brain dynamics predictive of response to psilocybin for treatment-resistant depression. Brain communications. vol 6. issue 2. 2024-03-22. PMID:38515439. |
psilocybin therapy for depression has started to show promise, yet the underlying causal mechanisms are not currently known. |
2024-03-22 |
2024-03-24 |
Not clear |
| Yasir Çatal, Georg Northof. Where do the symptoms come from in depression? Topography and dynamics matter. Brain communications. vol 6. issue 2. 2024-03-22. PMID:38515441. |
this scientific commentary refers to 'brain dynamics predictive of response to psilocybin for treatment-resistant depression', by vohryzek |
2024-03-22 |
2024-03-24 |
Not clear |
| Adam W Levin, Rafaelle Lancelotta, Nathan D Sepeda, Natalie Gukasyan, Sandeep Nayak, Theodore L Wagener, Frederick S Barrett, Roland R Griffiths, Alan K Davi. The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. PloS one. vol 19. issue 3. 2024-03-14. PMID:38483940. |
we examined if the therapeutic alliance between study participants and intervention facilitators in a psilocybin-assisted therapy (pat) trial changed over time and whether there were relationships between alliance, acute psilocybin experiences, and depression outcomes. |
2024-03-14 |
2024-03-17 |
human |
| Adam W Levin, Rafaelle Lancelotta, Nathan D Sepeda, Natalie Gukasyan, Sandeep Nayak, Theodore L Wagener, Frederick S Barrett, Roland R Griffiths, Alan K Davi. The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. PloS one. vol 19. issue 3. 2024-03-14. PMID:38483940. |
stronger total alliance one week after the final psilocybin session predicted depression scores at 4 weeks (r = -.85, p < .001), 3 months (r = -.52, p = .010), 6 months (r = -.77, p < .001), and 12 months (r = -.61, p = .001) post-intervention. |
2024-03-14 |
2024-03-17 |
human |
| Shuping Fang, Xin Yang, Wei Zhan. Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials. Frontiers in psychiatry. vol 15. 2024-03-01. PMID:38426002. |
efficacy and acceptability of psilocybin for primary or secondary depression: a systematic review and meta-analysis of randomized controlled trials. |
2024-03-01 |
2024-03-03 |
Not clear |
| Shuping Fang, Xin Yang, Wei Zhan. Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials. Frontiers in psychiatry. vol 15. 2024-03-01. PMID:38426002. |
in this study, we aim to evaluate the efficacy, acceptability and tolerability of psilocybin in the treatment of primary (major depressive disorder) or secondary (experiencing distress related to life-threatening diagnoses and terminal illness) depression. |
2024-03-01 |
2024-03-03 |
Not clear |
| Débora Copa, David Erritzoe, Bruna Giribaldi, David Nutt, Robin Carhart-Harris, Enzo Tagliazucch. Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity. Journal of affective disorders. 2024-02-29. PMID:38423367. |
predicting the outcome of psilocybin treatment for depression from baseline fmri functional connectivity. |
2024-02-29 |
2024-03-03 |
Not clear |
| Débora Copa, David Erritzoe, Bruna Giribaldi, David Nutt, Robin Carhart-Harris, Enzo Tagliazucch. Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity. Journal of affective disorders. 2024-02-29. PMID:38423367. |
psilocybin is a serotonergic psychedelic drug under assessment as a potential therapy for treatment-resistant and major depression. |
2024-02-29 |
2024-03-03 |
Not clear |
| Salma Laabi, Claire LeMmon, Callie Vogel, Mariana Chacon, Victor M Jimene. Deciphering psilocybin: Cytotoxicity, anti-inflammatory effects, and mechanistic insights. International immunopharmacology. vol 130. 2024-02-24. PMID:38401463. |
a decade of clinical research has indicated psilocybin's effectiveness in treating various neuropsychiatric disorders, such as depression and substance abuse. |
2024-02-24 |
2024-02-27 |
Not clear |
| Joshua D Rosenblat, Shakila Meshkat, Zoe Doyle, Erica Kaczmarek, Ryan M Brudner, Kevin Kratiuk, Rodrigo B Mansur, Christian Schulz-Quach, Rickinder Sethi, Amanda Abate, Shaun Ali, Jordan Bawks, Marc G Blainey, Elisa Brietzke, Victoria Cronin, Jessica Danilewitz, Shalini Dhawan, Anthony Di Fonzo, Melissa Di Fonzo, Pawel Drzadzewski, William Dunlop, Hajnalka Fiszter, Fabiano A Gomes, Smrita Grewal, Marisa Leon-Carlyle, Marilyn McCallum, Niki Mofidi, Hilary Offman, Jeremy Riva-Cambrin, Joel Schmidt, Mark Smolkin, Joan M Quinn, Andrea Zumrova, Michelle Marlborough, Roger S McIntyr. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med (New York, N.Y.). 2024-02-15. PMID:38359838. |
psilocybin-assisted psychotherapy for treatment resistant depression: a randomized clinical trial evaluating repeated doses of psilocybin. |
2024-02-15 |
2024-02-18 |
human |
| Scott T Aaronson, Zofia Koza. New evidence for flexible psilocybin dosing in patients with treatment-resistant depression. Med (New York, N.Y.). 2024-02-15. PMID:38359837. |
new evidence for flexible psilocybin dosing in patients with treatment-resistant depression. |
2024-02-15 |
2024-02-18 |
Not clear |
| Scott T Aaronson, Zofia Koza. New evidence for flexible psilocybin dosing in patients with treatment-resistant depression. Med (New York, N.Y.). 2024-02-15. PMID:38359837. |
psilocybin has demonstrated efficacy for treating depression; however, psychiatrically complex patients have been excluded from trials. |
2024-02-15 |
2024-02-18 |
Not clear |
| Tommaso Barba, Hannes Kettner, Caterina Radu, Joseph M Peill, Leor Roseman, David J Nutt, David Erritzoe, Robin Carhart-Harris, Bruna Giribald. Psychedelics and sexual functioning: a mixed-methods study. Scientific reports. vol 14. issue 1. 2024-02-07. PMID:38326446. |
convergent results were found in a controlled trial of psilocybin therapy versus an ssri, escitalopram, for depression. |
2024-02-07 |
2024-02-10 |
human |
| Joost J Breeksema, Alistair Niemeijer, Erwin Krediet, Tilman Karsten, Jeanine Kamphuis, Eric Vermetten, Wim van den Brink, Robert Schoever. Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study. Scientific reports. vol 14. issue 1. 2024-02-05. PMID:38316896. |
patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study. |
2024-02-05 |
2024-02-09 |
Not clear |
| Joost J Breeksema, Alistair Niemeijer, Erwin Krediet, Tilman Karsten, Jeanine Kamphuis, Eric Vermetten, Wim van den Brink, Robert Schoever. Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study. Scientific reports. vol 14. issue 1. 2024-02-05. PMID:38316896. |
psilocybin is the most researched classic psychedelic for treatment-resistant depression (trd). |
2024-02-05 |
2024-02-09 |
Not clear |
| Tessa Watford, Naqash Masoo. Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults - A Systematic Review. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 22. issue 1. 2024-01-22. PMID:38247407. |
with this, psilocybin could prove to be revolutionary in treating depression and become an alternative medication to ssris. |
2024-01-22 |
2024-01-24 |
human |
| Balázs Szigeti, Brandon Weiss, Fernando E Rosas, David Erritzoe, David Nutt, Robin Carhart-Harri. Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression. Psychological medicine. 2024-01-22. PMID:38247730. |
assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression. |
2024-01-22 |
2024-01-24 |
Not clear |
| Sabrina Wong, Angela T H Kwan, Kayla M Teopiz, Gia Han Le, Shakila Meshkat, Roger Ho, Giacomo d'Andrea, Bing Cao, Joshua D Di Vincenzo, Joshua D Rosenblat, Roger S McIntyr. A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review. Journal of affective disorders. 2024-01-20. PMID:38244804. |
a comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (nnt): a systematic review. |
2024-01-20 |
2024-01-23 |
Not clear |